300253 卫宁健康
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,295,802-32.27%2,782,2413,163,4253,092,8652,750,202
减:营业总成本1,538,894-13.32%2,513,1752,808,7462,828,5212,378,893
    其中:营业成本919,057-18.69%1,622,6151,740,8821,741,6131,475,529
               财务费用44,6815.38%57,44151,08039,66535,526
               资产减值损失(61,617)-4.22%(169,315)(136,735)(129,003)(83,931)
公允价值变动收益(15,191)-410.83%(28,588)(50,464)(24,888)155,547
投资收益(19,085)-36.40%(48,246)29,498(65,676)(39,040)
    其中:对联营企业和合营企业的投资收益(16,341)-43.77%(20,110)(31,011)(46,935)(45,084)
营业利润(262,980)-311.39%87,173341,43139,502374,662
利润总额(320,948)-359.05%86,959340,74738,541373,168
减:所得税费用(73,188)440.09%36,89223,13223,78319,434
净利润(247,760)-280.26%50,068317,61514,758353,734
减:非控股权益(6,374)-62.91%(37,826)(40,344)(93,882)(24,440)
股东净利润(241,386)-256.10%87,893357,959108,640378,174

市场价值指针
每股收益 (元) *-0.109-252.65%0.0410.1670.0510.177
每股派息 (元) *----0.0150.0200.0100.020
每股净资产 (元) *2.548-5.01%2.6742.5952.3312.328
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容